Ku ya 29 Mutarama 2025, itsinda ry’abashakashatsi b’Abashinwa ryasohoye inkuru ifite umutwe ugira uti “Neoadjuvant pyrotinib na trastuzumab muri kanseri y’ibere ya HER2 idafite igisubizo hakiri kare (NeoPaTHer): imikorere, umutekano, n’isesengura ry’ibipimo by’ubushakashatsi bw’ubushakashatsi bw’ubushakashatsi bw’ibizamini byinshi” mu kinyamakuru “Signal Transduction and Targeted Therapy”.
Kanseri y'ibere ya HER2-positive receptor 2 (HER2), ingana na ~15% kugeza 25% bya kanseri zose z'ibere, izwiho kuba ubwoko butandukanye kandi buteye ubwoba. Irangwa no kwiyongera cyane kwa HER2, receptor ya transmembrane tyrosine kinase itera kwiyongera no kubaho kw'uturemangingo twa kanseri. Abarwayi ba kanseri y'ibere ya HER2-positive bahura n'ibyago byinshi byo kongera kugaruka no gupfa ugereranije n'abafite izindi kanseri y'ibere, bigatuma iba indwara igoye cyane kuvura. Ariko, imiterere y'ubuvuzi bwa kanseri y'ibere ya HER2-positive yahindutse cyane mu myaka makumyabiri ishize, ahanini bitewe no gutangiza uburyo bwo kuvura bwibanda kuri HER2. By'umwihariko, kuza kwa trastuzumab byahinduye cyane inzira ya kanseri y'ibere ya HER2-positive iva ku ndwara yica cyane ijya ku yindi ifite ingaruka mbi cyane.
Hagati y'Ukwakira 2020 na Werurwe 2022, abarwayi 129 baturutse mu bitaro bitanu biyandikishije muri ubu bushakashatsi. Mu barwayi 129 biyandikishije, 62 (48.1%) bagaragaye ko ari abasubije MRI (itsinda A), 26 batasubije bakomeje izindi ngendo enye za TCbH (itsinda B), naho 41 batasubije bahabwa pyrotinib y'inyongera (itsinda C). Igipimo cya tpCR cyari 30.6% (95% CI: 20.6–43.0%) mu itsinda A, 15.4% (95% CI: 6.2–33.5%) mu itsinda B, na 29.3% (95% CI: 17.6–44.5%) mu itsinda C. Isesengura ry’impinduka mu buryo butandukanye ryagaragaje amahirwe angana yo kugera kuri tpCR hagati y’itsinda A na C (igipimo cy’amahirwe = 1.04, 95% CI: 0.40–2.70). Nta ngaruka mbi nshya zagaragaye iyo hongewemo pyrotinib. Abarwayi bafite impinduka za TP53 na PIK3CA bagaragaje igipimo gito cyo gusubiza igice cya mbere ugereranije n’abadafite cyangwa bafite impinduka imwe ya gene (36.0% ugereranije na 60.0%, P = 0.08). Ibi byavumbuwe bigaragaza ko kongeramo pyrotinib bishobora gufasha abarwayi badakira trastuzumab ya neoadjuvant hamwe na chemotherapy. Hakenewe iperereza ryinshi kugira ngo hamenyekane ibimenyetso bigaragaza inyungu z'abarwayi mu kongeramo pyrotinib.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Email：myimmnet@163.com
Amareferensi
https://www.nature.com/articles/s41392-025-02138-6
Igihe cyo kohereza: Gashyantare-08-2025